Diffusion of anti-VEGF injections in the Portuguese National Health System

BMJ Open

Volumn 5, Issue 11, 2015, Pages

  Marques, Ana Patrícia ^a   Macedo, António Filipe ^b   Perelman, Julian ^a   Aguiar, Pedro ^a   Rocha Sousa, Amândio ^c   Santana, Rui ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN A;

ANTAGONISTS AND INHIBITORS; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HUMAN; INJECTION; LONGITUDINAL STUDY; MACULAR DEGENERATION; MIDDLE AGED; PORTUGAL; STATISTICS AND NUMERICAL DATA;

DELIVERY OF HEALTH CARE; HEALTHCARE DISPARITIES; HUMANS; INJECTIONS; LONGITUDINAL STUDIES; MACULAR DEGENERATION; MIDDLE AGED; PORTUGAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85021858335     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/BMJOPEN-2015-009006     Document Type: Article

References (36)

1. Keenan TD, Wotton CJ, Goldacre MJ. Trends over time and geographical variation in rates of intravitreal injections in England. Br J Ophthalmol 2012;96:413-18.
2. Moutray T, Chakravarthy U. Age-related macular degeneration: current treatment and future options. Ther Adv Chronic Dis 2011;2:325-31.
3. Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292-9.
4. Brechner RJ, Rosenfeld PJ, Babish JD, et al. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 2011;151:887-95.e1.
5. Buitendijk GH, Rochtchina E, Myers C, et al. Prediction of age-related macular degeneration in the general population: the Three Continent AMD Consortium. Ophthalmology 2013;120:2644-55.
6. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-43.
7. Rein DB, Wittenborn JS, Zhang X, et al. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol 2009;127:533-40.
8. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012;119:1175-83.
9. Muñoz B, West SK, Rubin GS, et al. Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation Study. Arch Ophthalmol 2000;118:819-25.
10. Bonastre J, Le Pen C, Anderson P, et al. The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom. Eur J Health Econ 2002;3:94-102.
11. Weih LM, VanNewkirk MR, McCarty CA, et al. Age-specific causes of bilateral visual impairment. Arch Ophthalmol 2000;118:264-9.
12. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006;355:1409-12.
13. Coleman AL, Yu F, Ensrud KE, et al. Impact of age-related macular degeneration on vision-specific quality of life: follow-up from the 10-year and 15-year visits of the Study of Osteoporotic Fractures. Am J Ophthalmol 2010;150:683-91.
14. Wood JM, Lacherez P, Black AA, et al. Risk of falls, injurious falls, and other injuries resulting from visual impairment among older adults with age-related macular degeneration. Invest Ophthalmol Vis Sci 2011;52:5088-92.
15. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
16. Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. Lancet 2012;379:1728-38.
17. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 2013;120:2300-9.
18. Michels S, Becker M, Wachtlin J, et al. The intravitreal injection: variations in regulations, cost and reimbursement in Europe. Spektrum Augenheilkd 2012;26:2-6.
19. Zampros I, Praidou A, Brazitikos P, et al. Antivascular endothelial growth factor agents for neovascular age-related macular degeneration. J Ophthalmol 2012;2012:319728.
20. Saeed MU, Gkaragkani E, Ali K. Emerging roles for antiangiogenesis factors in management of ocular disease. Clin Ophthalmol 2013;6:533-43.
21. Kovach JL, Schwartz SG, Flynn HW Jr, et al. Anti-VEGF treatment strategies for wet AMD. J Ophthalmol 2012;2012:786870.
22. Thetford C, Hodge S, Harding S, et al. Living with age-related macular degeneration treatment: patient experiences of being treated with ranibizumab (Lucentis)(R) intravitreal injections. Br J Vis Impairm 2013;31:89-101.
23. Cheung N, Lam DS, Wong TY. Anti-vascular endothelial growth factor treatment for eye diseases. BMJ 2012;344:e2970.
24. Stein JD, Hanrahan BW, Comer GM, et al. Diffusion of technologies for the care of older adults with exudative age-related macular degeneration. Am J Ophthalmol 2013;155:688-96, 696. e1-2.
25. Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 2008;115:1837-46.
26. Ferris FL III, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology 2013;120:844-51.
27. INE. Censos - Resultados definitivos. Portugal-2011, 2014 (cited 28 April 2014). http://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_publicacoes&PUBLICACOESpub_boui=73212469&PUBLICACOESmodo=2
28. Beaghole R, Bonita R, Kjellstrom T. Basic epidemiology. Updated reprint ed. Geneva: World Health Organization, 1993.
29. Ballinger GA. Using generalized estimating equations for longitudinal data analysis. Organ Res Methods 2004;7:127-50.
30. Ministry of Health. Portal da Saúde. Lisboa: Health Ministry, 2014 (cited 10 January 2014). http://www.portaldasaude.pt/portal
31. Azuero A, Pisu M, McNees P, et al. An application of longitudinal analysis with skewed outcomes. Nurs Res 2010;59:301-7.
32. Hutton D, Newman-Casey PA, Tavag M, et al. Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period. Health Aff (Millwood) 2014; 33:931-9.
33. Hawlina M. UEMS survey highlights accessibility disparities, inconsistent policies for anti-VEGF treatment across Europe. Ocular Surgery News Europe Edition, 2015:5.
34. Koppens JM, Dai S, Mora J. Factors related to non-attendance in a public eye clinic. Clin Experiment Ophthalmol 2005;33:553-4.
35. Larson SL, Fleishman JA. Rural-urban differences in usual source of care and ambulatory service use: analyses of national data using urban influence codes. Med Care 2003;41(Suppl 7): III65-74.
36. Ng M, Nathoo N, Rudnisky CJ, et al. Improving access to eye care: teleophthalmology in Alberta, Canada. J Diabetes Sci Technol 2009;3:289-96.